Retatrutide vs SLU-PP-332

Retatrutide and SLU-PP-332 are research compounds investigated for metabolic health, but they operate through entirely different biological mechanisms. Retatrutide is a triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly, with robust clinical data including Phase 2 and Phase 3 trials demonstrating substantial weight loss and glycemic improvements. In contrast, SLU-PP-332 is a small-molecule pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ) developed at Washington University, designed to mimic the transcriptional effects of aerobic exercise. Critically, SLU-PP-332 has no human data, with all evidence derived from murine models. This comparison highlights the tradeoffs between clinical-stage hormonal modulation and preclinical transcriptional activation, emphasizing differences in evidence maturity, mechanistic specificity, and translational readiness.

Retatrutide is positioned as a pioneering triple agonist that simultaneously targets GIP, GLP-1, and glucagon receptors, a mechanism designed to optimize weight loss and improve glycemic control. In a Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), participants receiving a 12 mg dose experienced a remarkable average body weight reduction of 24.2% over 48 weeks, with all subjects losing a minimum of 5% of their baseline weight. Ongoing Phase 3 TRIUMPH trials, including TRIUMPH-4 (results anticipated in December 2025), suggest potential weight loss of up to 71.2 lbs, alongside reported alleviation of osteoarthritis symptoms. The mechanism of action involves the activation of incretin and glucagon pathways, contributing to appetite suppression, enhanced energy expenditure, and improved insulin sensitivity. Given the robust data derived from large, randomized, placebo-controlled trials, researchers can have high confidence in the efficacy and safety profiles of retatrutide, with FDA approval expected around 2027–2028.

SLU-PP-332 is a noteworthy small-molecule pan-agonist that targets estrogen-related receptors (ERRα, ERRβ, ERRγ), with its discovery originating from Washington University in St. Louis. This compound activates a gene program associated with aerobic exercise, leading to increased oxidative muscle fiber content and enhanced mitochondrial respiration in murine models, even in the absence of physical training. Unlike AICAR, which primarily activates AMPK, SLU-PP-332 directly influences the transcriptional regulators of oxidative metabolism, potentially fostering a more sustained activation of endurance-related pathways. Preclinical studies have shown promising results, including protection against muscular dystrophy and improvements in various metabolic parameters. However, the absence of human clinical trials presents a significant limitation, as all existing data are derived from rodent studies. This lack of human evidence raises questions about pharmacokinetics, safety, and efficacy, necessitating cautious interpretation of these findings as preliminary and emphasizing the need for further research to establish dose-response relationships and long-term effects.

While both retatrutide and SLU-PP-332 are under investigation for their roles in metabolic health, their specific research applications differ significantly. Retatrutide is primarily focused on weight management and glycemic control, with a substantial body of human data supporting its efficacy in reducing body weight and improving metabolic outcomes in individuals with type 2 diabetes. In contrast, SLU-PP-332 is being explored for its potential to enhance body composition by increasing oxidative muscle fiber content and improving exercise capacity without the need for physical training. Although both compounds impact metabolic pathways, retatrutide operates through hormonal mechanisms that regulate appetite and energy expenditure, while SLU-PP-332 engages in tissue-specific modulation of muscle metabolism at the transcriptional level. Consequently, researchers should consider their study objectives—whether they prioritize systemic metabolic regulation (favoring retatrutide) or tissue-specific adaptations (favoring SLU-PP-332)—to make informed selections.

The safety profile of retatrutide has been extensively characterized through human clinical trials, revealing that gastrointestinal side effects, such as nausea, vomiting, diarrhea, and constipation, are dose-dependent, affecting 13–63% of participants across various dose groups. These side effects are generally mild to moderate and may be partially alleviated by initiating treatment at lower doses (e.g., 2 mg vs. 4 mg). Additionally, dose-dependent increases in heart rate were observed, peaking at 24 weeks before declining, a phenomenon consistent with other incretin-based therapies. In stark contrast, SLU-PP-332 lacks any human safety data, with all available information stemming from mouse studies where twice-daily dosing was tolerated without reported toxicity. This absence of human data represents a considerable risk for translational research, as potential off-target effects, metabolic interactions, and long-term safety profiles remain unassessed. Researchers must weigh the well-established safety profile of retatrutide against the uncertainties surrounding SLU-PP-332, which is still in the preclinical stage.